Article

Enzyme may halt progression of diabetic retinopathy

Fort Lauderdale, FL-The use of an enzyme to liquefy the vitreous can induce posterior vitreous detachment (PVD) and could potentially halt the progression of diabetic retinopathy, reported Baruch D. Kuppermann, MD, PhD, during of the annual meeting of the Association for Research in Vision and Ophthalmology here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
Related Content
Q&A: The potential impact of vitamin D on retinal surgery
August 3rd 2025

Q&A: The potential impact of vitamin D on retinal surgery

3 Things You Should Know About the GA Pipeline
August 3rd 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

FDA approves Lenz Therapeutics’ VIZZ for the treatment of presbyopia
August 3rd 2025

FDA approves Lenz Therapeutics’ VIZZ for the treatment of presbyopia

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 3rd 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: A VERONA trial update with Yasha S. Modi, MD
August 3rd 2025

Q&A: A VERONA trial update with Yasha S. Modi, MD

EyePoint completes enrollment of LUGANO and LUCIA trials
August 3rd 2025

EyePoint completes enrollment of LUGANO and LUCIA trials

© 2025 MJH Life Sciences

All rights reserved.